Sanquin Plasma Revenue and Competitors
Estimated Revenue & Valuation
- Sanquin Plasma's estimated annual revenue is currently $20.1M per year.
- Sanquin Plasma's estimated revenue per employee is $201,000
Employee Data
- Sanquin Plasma has 100 Employees.
- Sanquin Plasma grew their employee count by -31% last year.
Sanquin Plasma's People
| Name | Title | Email/Phone |
|---|
Sanquin Plasma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.9M | 60 | 5% | N/A | N/A |
#2 | $43.8M | 203 | 13% | N/A | N/A |
#3 | $51.9M | 211 | -1% | N/A | N/A |
#4 | $32.2M | 142 | 8% | N/A | N/A |
#5 | $237.8M | 1033 | 6% | N/A | N/A |
#6 | $3.8M | 19 | 46% | N/A | N/A |
#7 | $237.8M | 1033 | 6% | N/A | N/A |
#8 | $20.1M | 100 | -31% | N/A | N/A |
#9 | $75M | 373 | -8% | N/A | N/A |
#10 | $2M | 10 | 25% | N/A | N/A |
What Is Sanquin Plasma?
From our home base in Amsterdam, the Netherlands, Sanquin Plasma Products B.V. produces and exports a broad range of pharmaceuticals for patients throughout the world. Our pharmaceuticals are derived from blood plasma and used for a large number of disorders, many of which life-threatening.
keywords:N/A
N/A
Total Funding
100
Number of Employees
$20.1M
Revenue (est)
-31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sanquin Plasma News
CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), LFB (France), Biotest (Germany), Sanquin...
Some of the Top companies Influencing in this Market include:CSL, ADMA Biologics, Sanquin, Baxter International, Octapharma, Cerus Corp,...
Plasma Protease C1-inhibitor Treatment Market Size, Share, Growth 2022-2029| Key Players Shire plc, CSL Limited, Sanquin, Pharming Group N.V..
Other Companies in Amsterdam
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 100 | 9% | N/A |
#2 | $14.5M | 100 | 1% | N/A |
#3 | $14M | 100 | -4% | N/A |
#4 | $12.5M | 100 | 20% | N/A |
#5 | $14.5M | 100 | N/A | N/A |